<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559530</url>
  </required_header>
  <id_info>
    <org_study_id>14186</org_study_id>
    <nct_id>NCT03559530</nct_id>
  </id_info>
  <brief_title>Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization</brief_title>
  <official_title>Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acinetobacter baumannii is an opportunist pathogen that has become increasingly important&#xD;
      over recent years as a cause of nosocomial infections. Ventilator-associated pneumonia,&#xD;
      central line-associated bloodstream infection and bone and soft tissue infections secondary&#xD;
      to open fractures are among the conditions most associated with this agent .&#xD;
&#xD;
      Attention is drawn not only to the increasing incidence of this agent over the last few years&#xD;
      but also to the rapid worsening of its susceptibility to antimicrobial agents, including&#xD;
      carbapenems. Few therapeutic options are available for treating pan-resistant strains:&#xD;
      colistin and tigecycline has been used, but resistance to these options frequently emerges in&#xD;
      clinical practice. Taking into account the fact that fewer new antimicrobial agents are being&#xD;
      validated and introduced into clinical practice, the growing prevalence of isolates with&#xD;
      these high levels of resistance is becoming a matter of increasing concern.&#xD;
&#xD;
      Certain risk factors have also been correlated with infection related to A. baumannii. The&#xD;
      most important are prolonged hospitalization in intensive care units and use of invasive&#xD;
      devices. Another important risk factor is severe trauma: A. baumannii is associated with&#xD;
      invasive infections, including osteomyelitis following open fracture reduction. Studies that&#xD;
      included military personnel and civilians involved in the recent conflicts in Iraq and&#xD;
      Afghanistan have shown high prevalence of A. baumannii as causative agent in cases of&#xD;
      osteomyelitis secondary to traumatic injuries. Also, in Brazil, a retrospective study that&#xD;
      analyzed 101 cases of osteomyelitis due to Gram-negative bacilli showed that A. baumannii was&#xD;
      the second most prevalent agent and that it had a high degree of antimicrobial resistance,&#xD;
      particularly to carbapenems.&#xD;
&#xD;
      The objectives of this retrospective study are: 1. clinically and epidemiologically&#xD;
      characterize 241 patients with osteomyelitis related to A. baumannii who were admitted at the&#xD;
      Institute of Orthopedics and Traumatology, Hospital das Clínicas, University of São Paulo; 2.&#xD;
      to describe the antimicrobial susceptibility profile of A. baumannii strains isolated; 3. to&#xD;
      evaluate the patients' outcomes (remission, recurrence, limb amputation or death) according&#xD;
      to the antimicrobial treatment used, including tigecycline; 4. to compare efficacy and safety&#xD;
      profiles of tigecycline, colistin and ampicillin-sulbactan among patients with&#xD;
      carbapenem-resistant A. baumannii related osteomyelitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION Acinetobacter baumannii is an opportunist pathogen that has become increasingly&#xD;
      important over recent years as a cause of nosocomial infections (1,2). Ventilator-associated&#xD;
      pneumonia, central line-associated bloodstream infection and bone and soft tissue infection&#xD;
      secondary to open fractures are among the conditions most associated with this agent.&#xD;
&#xD;
      Attention is drawn not only to the increasing incidence of this agent over the last few years&#xD;
      but also to the rapid worsening of its susceptibility to antimicrobial agents, including&#xD;
      carbapenems. Among the striking characteristics of this species is its high capacity to&#xD;
      develop antimicrobial resistance. The most important types of resistance are, firstly,&#xD;
      intrinsic resistance related to the association between diminished permeability of the&#xD;
      external membrane and constitutive expression of efflux pumps; and secondly, acquisition of&#xD;
      genetic elements, which might be resistance genes or insertion elements that, in association&#xD;
      with the chromosomal genes of this bacterium, can trigger expression of resistance and great&#xD;
      ability to survive in the environment, which is commonly related to production of biofilm&#xD;
      (7). All these characteristics have been correlated with emergence of multiresistant and&#xD;
      pan-resistant strains of A. baumannii. Few therapeutic options are available for treating&#xD;
      pan-resistant strains: colistin and tigecycline has been used, but resistance to these&#xD;
      options frequently emerges in clinical practice. Taking into account the fact that fewer new&#xD;
      antimicrobial agents are being validated and introduced into clinical practice, the growing&#xD;
      prevalence of isolates with these high levels of resistance is becoming a matter of&#xD;
      increasing concern. The formerly abundant flow of provision of new antibiotics of&#xD;
      ever-broader spectrum has been shown to be a non-renewable resource.&#xD;
&#xD;
      Certain risk factors have also been correlated with occurrence of A. baumannii. The most&#xD;
      important are prolonged hospitalization in intensive care units and use of invasive devices&#xD;
      .Another important risk factor is severe trauma: A. baumannii is associated with invasive&#xD;
      infections, including osteomyelitis following open fracture reduction. Studies that included&#xD;
      military personnel and civilians involved in the recent conflicts in Iraq and Afghanistan&#xD;
      have shown high prevalence of A. baumannii as causative agent in cases of osteomyelitis&#xD;
      secondary to traumatic injuries. Also, in Brazil, a retrospective study that analyzed 101&#xD;
      cases of osteomyelitis due to Gram-negative bacilli showed that A. baumannii was the second&#xD;
      most prevalent agent, showing a high profile of antimicrobial resistance, particularly to&#xD;
      carbapenems.&#xD;
&#xD;
      At the Institute of Orthopedics and Traumatology, Hospital das Clínicas, University of São&#xD;
      Paulo, a Brazilian reference center that provides care for high-complexity orthopedic cases,&#xD;
      241 cases of osteomyelitis related to A. baumannii were treated between 2007 and 2014. All&#xD;
      cases had microbiological confirmation, with positive cultures of bone tissue.&#xD;
&#xD;
      OBJECTIVES&#xD;
&#xD;
        1. Clinical and epidemiological characterization of 241 cases of osteomyelitis related to&#xD;
           A. baumannii who were admitted at the Institute of Orthopedics and Traumatology,&#xD;
           Hospital das Clínicas, University of São Paulo;&#xD;
&#xD;
        2. To describe the antimicrobial susceptibility profile of A. baumannii strains isolated;&#xD;
&#xD;
        3. To evaluate the patients' outcomes (remission, recurrence, limb amputation or death)&#xD;
           according to the antimicrobial treatment used, including tigecycline.&#xD;
&#xD;
        4. To compare efficacy and safety profiles of tigecycline, colistin and&#xD;
           ampicillin-sulbactan among patients with carbapenem-resistant A. baumannii related&#xD;
           osteomyelitis.&#xD;
&#xD;
      METHODS This study will include data about all 241 patients with A. baumannii-related&#xD;
      osteomyelitis admitted at our institution from 2007 to 2014. According to the institution´s&#xD;
      protocol, diagnosis of osteomyelitis was based on the clinical history, infectious signs and&#xD;
      symptoms and positive culture of bone tissue for A. baumannii. Bone samples were obtained&#xD;
      from biopsy fragments identified as bone or medullary canal tissue (cortical bone and&#xD;
      medullary canal aspirates) obtained through surgical procedures. All specimens were sent to&#xD;
      the microbiology laboratory in thioglycolate culturing medium. The first reading was made 24&#xD;
      hours after incubation started and if the samples showed bacterial growth, the material was&#xD;
      seeded in blood agar and MacConkey agar media. Bacterioscopic examinations were also&#xD;
      performed. Subsequently, Gram-negative bacteria were identified by means of Vitek.&#xD;
      Non-fermenting and Gram-positive bacteria were identified manually and a susceptibility test&#xD;
      was performed using disk-diffusion. The minimum inhibitory concentrations were released in&#xD;
      accordance with the CLSI criteria.&#xD;
&#xD;
      The following variables will be collected and analyzed for clinical characterization and&#xD;
      outcomes evaluation:&#xD;
&#xD;
        -  Gender;&#xD;
&#xD;
        -  Age;&#xD;
&#xD;
        -  Affected bones;&#xD;
&#xD;
        -  Time of disease symptoms until hospital admission;&#xD;
&#xD;
        -  Osteomyelitis-related symptoms;&#xD;
&#xD;
        -  Previous antimicrobial use (before A. baumannii-positive culture);&#xD;
&#xD;
        -  Classification of osteomyelitis (according to Waldwogel´s system);&#xD;
&#xD;
        -  Presence of comorbidities (diabetes mellitus, active neoplasia, HIV infection,&#xD;
           intravenous drug use, smoking, peripheral venous/arterial disease, alcoholism, open&#xD;
           fracture, previous orthopedic surgery, imunossupressive conditions);&#xD;
&#xD;
        -  ASA score;&#xD;
&#xD;
        -  A. baumannii susceptibility profile;&#xD;
&#xD;
        -  Antimicrobial drugs prescribed for A. baumannii-related infection;&#xD;
&#xD;
        -  Antimicrobial drugs prescribed for concomitant infections;&#xD;
&#xD;
        -  Antimicrobial-related side effects;&#xD;
&#xD;
        -  Creatinine evolution following A. baumannii-related infection treatment;&#xD;
&#xD;
        -  ESR, CPR and hemogram evolution following A. baumannii-related infection treatment;&#xD;
&#xD;
        -  AST and ALT evolution following A. baumannii-related infection treatment;&#xD;
&#xD;
        -  Radiological evolution of affected bone following A. baumannii-related infection&#xD;
           treatment;&#xD;
&#xD;
        -  Outcomes 6-month after A. baumannii-related infection treatment (disease remission,&#xD;
           amputation of the affected limb, infection relapse, death and loss to follow-up).&#xD;
           Disease remission will be defined as absence of signs of infection at the end of&#xD;
           follow-up period.&#xD;
&#xD;
      Data analysis will be descriptive for all above mentioned variables among the 241 patients&#xD;
      with A. baumanni-related osteomyelitis. Among those with infection related to carbapenem&#xD;
      resistant-isolates, the variables concerning safety and efficacy of chosen antimicrobial&#xD;
      regimen, colistin, ampicillin-sulbactan or tigeciclyne (antimicrobial-related side effects;&#xD;
      creatinine evolution; ESR, CPR and hemogram evolution will be compared using chi-square test&#xD;
      or Fisher's exact test for categoric variables and ANOVA test for continuous variables.&#xD;
      Radiological variables and outcomes will be compared using chi-square test or Fisher's exact&#xD;
      test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the Clinical and Epidemiological Profile of Patients With Infection</measure>
    <time_frame>6 months</time_frame>
    <description>Distribution of the clinical and epidemiological characteristics studied among the patients. Use of percentage and average for description.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A. Baumannii Susceptibility Profile</measure>
    <time_frame>6 months</time_frame>
    <description>A. baumannii isolates susceptible to the tested antimicrobials</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">262</enrollment>
  <condition>Osteomyelitis</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with microbiologically proven A. baumannii-related osteomyelitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antimicrobial</intervention_name>
    <description>Antimicrobial therapy according to A. baumannii susceptibility profile</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include data about all 241 patients with A. baumannii-related osteomyelitis&#xD;
        admitted at our institution from 2007 to 2014. According to the institution´s protocol,&#xD;
        diagnosis of osteomyelitis was based on the clinical history, infectious signs and symptoms&#xD;
        and bone tissue culturing that was positive for A. baumannii.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Microbiologically confirmed osteomyelitis related to Acinetobacter baumannii&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Impossibility to review data in medical records;&#xD;
&#xD;
          2. Culture results with A. baumannii considered as colonization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Lucia L Lima, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Ortopedia e Traumatologia do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <results_first_submitted>July 10, 2020</results_first_submitted>
  <results_first_submitted_qc>April 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Priscila Rosalba Domingos de Oliveira</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>osteomyelitis</keyword>
  <keyword>Acinetobacter baumannii</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03559530/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The initial database consisted of 262 patients. It was possible to collect data for 171 patients. Reasons for not including 91 patients:&#xD;
non-location of medical records: 44;&#xD;
culture results not considered for treatment: 29;&#xD;
duplicate cases: 8;&#xD;
other species of Acinetobacter: 7;&#xD;
contamination / colonization: 3.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Carbapenem Susceptible A. Baumannii</title>
          <description>106 patients with osteomyelitis related to carbapenem-susceptible A. baumannii</description>
        </group>
        <group group_id="P2">
          <title>XDR Acinetobacter Baumannii</title>
          <description>For this analysis, the 65 patients with XDR A. baumannii -related osteomyelitis, always resistant to carbapenems, treated with colistin or tigecycline were included.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>non-location of medical records</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>culture results not considered for treat</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>duplicate cases</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other species of Acinetobacte</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>contamination / colonization</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with bone tissue culture positive for Acinetobacter baumannii submitted to surgical procedures to treat osteomyelitis.</population>
      <group_list>
        <group group_id="B1">
          <title>Patients</title>
          <description>All patients with bone tissue culture positive for Acinetobacter baumannii submitted to surgical procedures to treat osteomyelitis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Infections</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="171"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" lower_limit="6" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="171"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="171"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Description of the Clinical and Epidemiological Profile of Patients With Infection</title>
        <description>Distribution of the clinical and epidemiological characteristics studied among the patients. Use of percentage and average for description.</description>
        <time_frame>6 months</time_frame>
        <population>Described above.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Patients with A. baumannii-related osteomyelitis</description>
          </group>
        </group_list>
        <measure>
          <title>Description of the Clinical and Epidemiological Profile of Patients With Infection</title>
          <description>Distribution of the clinical and epidemiological characteristics studied among the patients. Use of percentage and average for description.</description>
          <population>Described above.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Relapse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Amputation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lost follow-up</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death related to A. baumannii infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death not related to A. baumannii infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A. Baumannii Susceptibility Profile</title>
        <description>A. baumannii isolates susceptible to the tested antimicrobials</description>
        <time_frame>6 months</time_frame>
        <population>Percentage of patients with carbapenem-susceptible isolates of A. baumannii</population>
        <group_list>
          <group group_id="O1">
            <title>Susceptibility Profile of A. Baumannii Isolates Over Time</title>
            <description>Variation in the susceptibility of A. baumannii isolates to antimicrobials over time from 2007 to 2015.</description>
          </group>
        </group_list>
        <measure>
          <title>A. Baumannii Susceptibility Profile</title>
          <description>A. baumannii isolates susceptible to the tested antimicrobials</description>
          <population>Percentage of patients with carbapenem-susceptible isolates of A. baumannii</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Adverse events (AE) reported within 48 hours after initiation of treatment with colistin (CL) or tigecycline (TG) were analysed: renal impairment;liver alterations; nausea/vomiting; and skin rash. Any other AE that occurred during treatment, was classified as &quot;other event&quot;.&#xD;
AE were analyzed only for patients who received CL or TG. For this reason, there was no assessment of the occurrence of AE in patients in the &quot;Carbapenem Susceptible A. baumannii&quot; group, as they received neither CL nor TG.</desc>
      <group_list>
        <group group_id="E1">
          <title>XDR A. Baumannii</title>
          <description>Patients with microbiologically proven XDR A. baumannii-related osteomyelitis who received colistin or tigecycline for treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <description>Renal impairment</description>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver abnormalities</sub_title>
                <description>Liver abnormalities</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Priscila Rosalba Domingos de Oliveira</name_or_title>
      <organization>Unversidade de Sao Paulo</organization>
      <phone>551126616900</phone>
      <email>priscila.rosalba@hc.fm.usp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

